|
| Status |
Public on Oct 19, 2020 |
| Title |
Selective inhibition of JAK1 with filgotinib reverses pathogenic processes in the DSS preclinical model for IBD |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by array
|
| Summary |
The pathogenesis of inflammatory bowel diseases (IBD) is associated with a dysregulated mucosal immune response. The signaling of several cytokines regulating this immune response is mediated by kinases of the JAK family, i.e. JAK1, JAK2, JAK3 and TYK2. Filgotinib is a JAK1-selective inhibitor with demonstrated efficacy in phase 2 trials in patients with rheumatoid arthritis (RA) and Crohn’s disease (CD). Here, we investigated the effects of filgotinib on the DSS (dextran sulfate sodium) mouse model
|
| |
|
| Overall design |
Balb/cJ female mice were purchased from Janvier Labs (France) and housed in Galapagos animal facilities. All procedures were reviewed and approved by the Galapagos Ethical Committee for the Animal Care and Use . Chronic colitis was induced in eight weeks old mice by cyclical administration of 4% DSS via drinking water, involving 3 cycles of DSS for 4 days interrupted by washout periods of 3 days under regular drinking water. The mice (n=5 per group) were assigned in 3 groups: 1/ Drinking water, 2/ DSS in water and filgotinib vehicle 3/ DSS in water and filgotinib. Filgotinib was given at 30 mg/kg, once a day by oral gavage.
|
| |
|
| Contributor(s) |
Ongenaert M |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| Submission date |
Oct 20, 2017 |
| Last update date |
Jul 25, 2021 |
| Contact name |
Maté Ongenaert |
| E-mail(s) |
mate.ongenaert@glpg.com
|
| Phone |
+3215342927
|
| Organization name |
Galapagos
|
| Street address |
Generaal De Wittelaan L11A3
|
| City |
Mechelen |
| ZIP/Postal code |
2800 |
| Country |
Belgium |
| |
|
| Platforms (1) |
| GPL21163 |
Agilent-074809 SurePrint G3 Mouse GE v2 8x60K Microarray [Probe Name version] |
|
| Samples (15)
|
|
| Relations |
| BioProject |
PRJNA415138 |
Less...
More...